ライフサイエンスコーパス: run-in period

1 cts of olive oil intake and a habitual diet (run-in period).

2 placebo (n = 12) after a 3- to 5-day placebo run-in period.

3 s, following a 2-week, single-blind, placebo run-in period.

4 zed parallel intervention preceded by a 2-wk run-in period.

5 esponded (ie, entrained) after a tasimelteon run-in period.

6 or 84 days after a 14-day open-label placebo run-in period.

7 ionate (500 mug twice daily) during a 6-week run-in period.

8 re enrolled into a 2-month dose-optimisation run-in period.

9 buffet test meal obtained during the placebo run-in period.

10 on diagnosis claims during an initial 2-year run-in period.

11 concentration and eligibility over a 4-week run-in period.

12 assessing medical problems at the end of the run-in period.

13 cantly reduced during the ICS versus placebo run-in periods: 0.18 mm/wk (SD, 0.55 mm/wk) versus 0.45

14 After a 2-wk run-in period, 152 healthy men and women (aged 40-70 y)

15 After the run-in period, 19 patients randomized to the control gro

16 After a 1 week run-in period, 24 patients with constipation-predominant

17 After a 4-wk run-in period, 240 hypercholesterolemic but otherwise he

18 After a run-in period, 254 patients were randomly assigned to pl

19 After a 4-week run-in period, 304 participants were randomized to the f

20 After a single-blind, 4-5-week placebo run-in period, 332 patients were randomised double-blind

21 three to eight times a day during the study run-in period (362 of 621 who started) were randomly ass

22 Following a 4-wk run-in period, 39 corticosteroid-dependent asthmatic pat

23 After a 2-wk run-in period, 44 Europeans and 40 Indo-Asian Sikhs were

24 After a run-in period, 518 individuals with previous vascular di

25 Of 202 patients treated during the run-in period, 73 patients had tumor shrinkage of > or =

26 duced FEV1 fall was 27.9 +/- 1.4% during the run-in period, 8.1 +/- 1.2% (70.3 +/- 4.1% bronchoprotec

27 During the 2-mo run-in period, all patients received fluticasone; they t

28 After a 2-week run-in period, all patients were given 50 mg/d of sertra

29 e scheduled (416 liters per minute after the run-in period and 414 liters per minute after the treatm

30 bjects were tested during a baseline placebo run-in period and retested after 28-days of drug (n = 21

31 red to the hip protector use during a 2-week run-in period and were enrolled.

32 egan with a 4-wk, placebo (olive oil; 4 g/d) run-in period and were then randomly assigned to 4 wk of

33 After 3-wk run-in periods and separated by a 5-wk washout period, 2

34 Prerandomization run-in periods are being used to select or exclude patie

35 mm Hg were randomized after a 2-week placebo run-in period (baseline) in a double-blind, crossover fa

36 Run-in periods can dilute or enhance the clinical applic

37 After a 7-d cocoa-free run-in period, cocoa or flavanol-poor placebo (approxima

38 n period, the nature of treatment during the run-in period, concurrent treatment during the treatment

39 undergoing a 1-month, single-blind, placebo run-in period during an existing clinical trial to 3 gro

40 After a 3-wk run-in period during which all participants received a l

41 METHODS AND After a 4-week run-in period during which fruit and vegetable intake wa

42 sover dietary intervention study with a 14-d run-in period during which subjects consumed their habit

43 hronic hemodialysis completed a 16- to 20-wk run-in period, during which maintenance ivID and rhEPO w

44 After a 4-week open-label run-in period, during which time all patients received s

45 After an open-label, run-in period, each patient was randomly assigned (doubl

46 1 patients entering sequential, single-blind run-in periods (enalapril 10 mg twice daily for 2 weeks

47 Participants completed a 2- to 8-week run-in period followed by 3 crossover periods with daily

48 M was consumed for 11 d, consisting of a 6-d run-in period followed by a 4-d balance period and 1 run

49 of clinical trials, but the implications of run-in periods for interpreting the results of clinical

50 We excluded 1,546 patients during a 2-month run-in period from July 1, 2011, to August 31, 2011, res

51 Following a 2-week run-in period, HAE patients received 8 weekly rhC1INH ad

52 reatment phase that most closely matched the run-in period in terms of ambient temperature) compared

53 All subjects started with a 2-wk run-in period in which they consumed 150 mL control soy-

54 derate Alzheimer's disease entered a 12-week run-in period in which they were randomly allocated done

55 ) subjects discontinued the study during the run-in period, including 1102 (10.5%) during the enalapr

56 ciprocalised creatinine was evident over the run-in period (mean 1/creatinine before MMF=0.005739-0.0

57 During a run-in period of 2 to 8 weeks, patients were instructed

58 All patients completed a run-in period of 3 weeks on a regimen based on standard

59 us ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks.

60 ontrolled trials (RCTs) with a stable asthma run-in period of 4 weeks or more, an intervention to red

61 mized controlled trials with a stable asthma run-in period of 4 weeks or more, an intervention to sto

62 After a run-in period of 4 weeks, in which all patients received

63 During the 3-week run-in period of a randomized trial, 123 healthy individ

64 ject body weights.After a 2-wk provided-food run-in period of consuming a Western-style diet, 49 men

65 F, in relation to treatment failure from the run-in period of open-label inhaled fluticasone, and the

66 at higher risk for noncompletion during the run-in period of PARADIGM-HF.

67 hange intakes from those observed during the run-in period of the buffet test meal (P = 0.78).

68 hma that was well controlled during a 6-week run-in period of treatment with inhaled triamcinolone (4

69 was suboptimally controlled during a 6-week run-in period of treatment with inhaled triamcinolone ac

70 After a 2-week run-in period on a control diet (37% total fat, 16% satu

71 than did olive oil intake (P < 0.05) and the run-in period (P < 0.005 and P < 0.05, respectively) and

72 increased HDL cholesterol compared with the run-in period (P < 0.05).

73 the butter period than in the olive oil and run-in periods (P < 0.0001).

74 After a 2-4 week run-in period, participants were randomly assigned (1:1)

75 After a 2-wk run-in period, participants were randomly assigned to co

76 After an active run-in period, participants were randomly assigned to re

77 After a 30-day run in period, patients were randomly assigned (1:1:1) t

78 After a run-in period, patients (N = 719) were randomized at 30

79 After a 1-week, single-blind, placebo, run-in period, patients received a double-blind, 11-week

80 After a 1- to 2-week run-in period, patients received either 12 mug of small-

81 After a 2-week placebo run-in period, patients received either montelukast (5-m

82 blind placebo plus diet (600 kcal/d deficit) run-in period, patients were randomized to receive place

83 After a 2-week single-blind placebo run-in period, patients were randomly assigned (1:1) by

84 After a 30-day run-in period, patients were randomly assigned (1:1:1) t

85 After a 4-week, single-masked run-in period, patients were randomly assigned to receiv

86 After the run-in period, patients with glycated haemoglobin of 8.0

87 After a 2-week run-in period receiving one inhalation per day via singl

88 Reports of clinical trials using run-in periods should indicate how this aspect of their

89 After a 24-h placebo run-in period, subjects received a placebo (n = 19) or 4

90 After a 2-week run-in period, subjects were assigned randomly to groups

91 After a 2-week run-in period, subjects were randomized into 3 treatment

92 Trial exemplifies the use of an active-drug run-in period that enhances clinical applicability by se

93 After a run-in period that included treatment with an inhaled co

94 The presence of a run-in period, the nature of treatment during the run-in

95 ts that would have been observed without the run-in period, the reported results overestimate the ben

96 dies of these drug classes should consider a run-in period to assess adherence and use a different st

97 After a run-in period to control for inhaled corticosteroid use,

98 -controlled study with a 2-week single-blind run-in period to determine baseline severity, followed b

99 After a 4-week run-in period to ensure insufficient response to standar

100 dy exemplifies the use of a prerandomization run-in period to exclude subjects who are nonadherent, w

101 E)-inhibitors were randomly assigned after a run-in period to oral ramipril 10 mg/day (n=8407), telmi

102 r exercise on two occasions during a placebo run-in period to receive 10 mg of montelukast (54 patien

103 concomitant preventive drugs) after a 28 day run-in period to three 28 day treatment cycles of subcut

104 r congestive heart failure typify the use of run-in periods to exclude patients who do not tolerate o

105 ized (after a 3-week, single-blind, placebo, run-in period) to 1 of 3 parallel, 6-month, double-blind

106 eline and tolerant of aspirin, over an 18-wk run-in period, to 325 mg aspirin or placebo on alternate

107 After an 8-9 month run-in period we asked patients, hospital staff and GPs

108 After a single-blind run-in period, we assigned patients, in a double-blind f

109 After a 4-week run-in period, we randomly assigned 317 subjects (age ra

110 After a 9-week run-in period, we randomly assigned patients with asthma

111 Screening procedures and a 3-week run-in period were added to increase the use of the mobi

112 olone acetonide during a 2-wk, single-blind, run-in period were randomized to inhaled fluticasone pro

113 corticosteroids during a 2-wk, single-blind, run-in period were randomized to treatment with salmeter

114 cipants who adhered to treatment during this run-in period were then randomly assigned to 46 weeks of

115 mples of reports of clinical trials in which run-in periods were used to exclude noncompliant subject

116 During the run-in period, when albuterol use was kept to a minimum,

117 ria at screening entered a 2-week open-label run-in period where they received beclometasone dipropio

118 After a 4-wk run-in period with a refined diet, we randomly allocated

119 After a run-in period with atorvastatin 10 mg daily, patients we

120 -C >130 mg/dl at screening entered an 8-week run-in period with atorvastatin 20 mg/day before randomi

121 omparing LLGR and 24-hour UFC in the placebo run-in period with values in the ICS treatment period by